Discounted Cash Flow
Heron Therapeutics, Inc. /De/
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
| Dividends | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2016 | $1.3m | $-173.1m | $-137.2m | -13537.4% | — |
| 2017 | $30.8m (2305.6%) | $-197.5m (-14.1%) | $-172.9m (-26.0%) | -641.9% (95.3%) | — |
| 2018 | $77.5m (151.8%) | $-178.8m (9.4%) | $-201.0m (-16.3%) | -230.8% (64.0%) | — |
| 2019 | $146.0m (88.4%) | $-204.7m (-14.5%) | $-131.7m (34.5%) | -140.3% (39.2%) | — |
| 2020 | $88.6m (-39.3%) | $-227.3m (-11.0%) | $-191.6m (-45.5%) | -256.4% (-82.8%) | — |
| 2021 | $86.3m (-2.6%) | $-220.7m (2.9%) | $-206.4m (-7.7%) | -255.6% (0.3%) | $-2.24 |
| 2022 | $107.7m (24.7%) | $-182.0m (17.5%) | $-148.7m (27.9%) | -169.1% (33.9%) | $-1.67 (25.4%) |
| 2023 | $127.0m (18.0%) | $-110.6m (39.3%) | $-60.3m (59.4%) | -87.0% (48.5%) | $-0.80 (52.1%) |
| 2024 | $144.3m (13.6%) | $-13.6m (87.7%) | $-24.2m (59.8%) | -9.4% (89.2%) | $-0.09 (88.8%) |
| 2025 | $154.9m (7.4%) | $-20.2m (-48.7%) | $-27.9m (-15.2%) | -13.0% (-38.5%) | $-0.12 (-33.3%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.